Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $44.9000 (-2.21%) ($44.9000 - $44.9000) on Fri. Apr. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.56% (three month average) | RSI | 50 | Latest Price | $44.9000(-2.21%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TGTX declines -1.7% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(67%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.78% in a week (0% probabilities). VIXM(-42%) VXX(-36%) UUP(-18%) IGOV(-4%) UNG(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.78% (StdDev 3.56%) | Hourly BBV | -0.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $38.12(-15.1%) | Inflection Point | Yes | Resistance Level | $46.34 | 5 Day Moving Average | $44.92(-0.04%) | 10 Day Moving Average | $45.64(-1.62%) | 20 Day Moving Average | $46.34(-3.11%) | To recent high | -17.1% | To recent low | 7.7% | Market Cap | $5.687b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |